MAR 0 6 2002 S/N 09/508,89

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

LEVESQUE ET AL.

Examiner:

B. SISSON

Serial No.:

09/508,891

Group Art Unit:

1655

Filed:

JUNE 2, 2000

Docket No.:

9555.96USWO

Title:

METHOD FOR THE IDENTIFICATION OF ESSENTIAL GENES AND

THERAPEUTIC TARGETS

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on February 25, 2002.

RESPONSE

MAR 1 4 2002

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed August 24, 2001, Applicants provide the following remarks. A three-month extension of time has been requested to extend the date for Response to February 24, 2002. Because February 24, 2002 falls on a Sunday, the Response is being timely filed on Monday, February 25, 2002.

REMARKS

The present application is directed to a novel assay useful in identifying whether genes are essential or dispensable. The claimed invention also provides a simple and efficient method of identifying genes which are essential under specific conditions. The essential gene test (EGT) is based on the premise that a mutation inactivating an essential gene should give rise *in vivo* to a lethal phenotype irrespective of the growth conditions. Thus, the present invention provides a novel method by which the user may define the function of thousands of sequences containing a complete open reading frame or parts thereof, or known and/or unknown genes in coding hypothetical proteins or products.